Nitric oxide and renal function in cirrhotic patients with ascites: From physiopathology to practice

European Journal of Gastroenterology and Hepatology

Volumn 16, Issue 6, 2004, Pages 567-570

  Grange J D ^a   Anniot, X ^a  

^a HÔPITAL TENON   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; AMINOGLYCOSIDE; AMOXICILLIN PLUS CLAVULANIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIBIOTIC AGENT; CEFOTAXIME; CYTOKINE; INTERLEUKIN 6; ISOSORBIDE MONONITRATE; LOSARTAN; NATRIURETIC FACTOR; NITRATE; NITRIC OXIDE; NITRITE; PROPRANOLOL DERIVATIVE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TUMOR NECROSIS FACTOR ALPHA;

ARTERY DILATATION; ASCITES; ASCITES FLUID; AUTONOMIC NERVOUS SYSTEM; BACTERIAL PERITONITIS; BLEEDING; CIRCULATION; CLINICAL TRIAL; CONCENTRATION (PARAMETERS); DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFECT; DRUG MEGADOSE; HUMAN; HYPOTENSION; INFECTION COMPLICATION; KIDNEY FAILURE; KIDNEY FUNCTION; LIVER CIRRHOSIS; LIVER DISEASE; LIVER TRANSPLANTATION; LOW DRUG DOSE; MEDICAL PRACTICE; METABOLIC DISORDER; MORTALITY; NEPHROTOXICITY; PATHOGENESIS; PATHOPHYSIOLOGY; PLASMA; PORTAL HYPERTENSION; PREDICTION; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; TREATMENT INDICATION; TREATMENT PLANNING; VASODILATATION;

ASCITES; HUMANS; KIDNEY; LIVER CIRRHOSIS; NITRIC OXIDE; PERITONITIS;

EID: 2542577732     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042737-200406000-00009     Document Type: Review

References (31)

1. Sansoe G, Silvano S, Mengozzi G, Smedile A, Todros L, Baronio M, et al. Systemic nitric oxide production and renal function in nonazotemic human cirrhosis: a reappraisal. Am J Gastroenterol 2002; 97:2383-2390.
2. Van Kats JP, Schalekamp MA, Verdouw PD, Duncker DJ, Danser AH. Intrarenal angiotensin II: interstitial and cellular levels and site of production. Kidney Int 2001; 60:2311-2317.
3. Blendis L, Wong F. Excess nitric oxide in preascites: another piece in the puzzle. Am J Gastroenterol 2002; 97:2167-2169.
4. Genesca J, Marti R, Rojo F, Campos F, Peribanez V, Gonzalez A, et al. Increased tumour necrosis factor alpha production in mesenteric lymph nodes of cirrhotic patients with ascites. Gut 2003; 52:1054-1059.
5. Wiest R, Das S, Cadelina G, Garcia-Tsao G, Milstien S, Groszmann RJ. Bacterial translocation in cirrhotic rats stimulates eNOS-derived NO production and impairs mesenteric vascular contractility. J Clin Invest 1999; 104:1223-1233.
6. Llovet JM, Moitinho E, Sala M, Bataller R, Rodriguez-Iglesias P, Castells A, et al. Prevalence and prognostic value of hepatocellular carcinoma in cirrhotic patients presenting with spontaneous bacterial peritonitis. J Hepatol 2000; 33:423-429.
7. Follo A, Llovet JM, Navasa M, Planas R, Forns X, Francitorra A, et al. Renal impairment after spontaneous bacterial peritonitis in cirrhosis: incidence, clinical course, predictive factors and prognosis. Hepatology 1994; 20:1495-1501.
8. Navasa M, Follo A, Filella X, Jimenez W, Francitorra A, Planas R, et al. Tumor necrosis factor and interleukin-6 in spontaneous bacterial peritonitis in cirrhosis: relationship with the development of renal impairment and mortality. Hepatology 1998; 27:1227-1232.
9. Jimenez W, Ros J, Morales-Ruiz M, Navasa M, Sole M, Colmenero J, et al. Nitric oxide production and inducible nitric oxide synthase expression in peritoneal macrophages of cirrhotic patients. Hepatology 1999; 30:670-676.
10. Bories PN, Campillo B, Azaou L, Scherman E. Long-lasting NO overproduction in cirrhotic patients with spontaneous bacterial peritonitis. Hepatology 1997; 25:1328-1333.
11. Ruiz-del-Arbol L, Urman J, Fernandez J, Gonzalez M, Navasa M, Monescillo A, et al. Systemic, renal, and hepatic hemodynamic derangement in cirrhotic patients with spontaneous bacterial peritonitis. Hepatology 2003; 38:1210-1218.
12. Abraldes JG, Tarantino I, Turnes J, Garcia-Pagan JC, Rodes J, Bosch J. Hemodynamic response to pharmacological treatment of portal hypertension and long-term prognosis of cirrhosis. Hepatology 2003; 37:902-908.
13. Wong F, Liu P, Blendis L. The mechanism of improved sodium homeostasis of low-dose losartan in preascitic cirrhosis. Hepatology 2002; 35:1449-1458.
14. De BK, Bandyopadhyay K, Das TK, Das D, Biswas PK, Majumdar D, et al. Portal pressure response to losartan compared with propranolol in patients with cirrhosis. Am J Gastroenterol 2003; 98:1371-1376.
15. Schepke M, Werner E, Biecker E, Schiedermaier P, Heller J, Neef M, et al. Hemodynamic effects of the angiotensin II receptor antagonist irbesartan in patients with cirrhosis and portal hypertension. Gastroenterology 2001; 121:389-395.
16. Hampel H, Bynum GD, Zamora E, El-Serag HB. Risk factors for the development of renal dysfunction in hospitalized patients with cirrhosis. Am J Gastroenterol 2001; 96:2206-2210.
17. Gines A, Fernandez-Esparrach G, Monescillo A, Vila C, Domenech E, Abecasis R, et al. Randomized trial comparing albumin, dextran 70, and polygeline in cirrhotic patients with ascites treated by paracentesis. Gastroenterology 1996; 111:1002-1010.
18. Sola-Vera J, Minana J, Ricart E, Planella M, Gonzalez B, Torras X, et al. Randomized trial comparing albumin and saline in the prevention of paracentesis-induced circulatory dysfunction in cirrhotic patients with ascites. Hepatology 2003; 37:1147-1153.
19. Henriksen JH, Gotze JP, Fuglsang S, Christensen E, Bendtsen F, Moller S. Increased circulating pro-brain natriuretic peptide (proBNP) and brain natriuretic peptide (BNP) in patients with cirrhosis: relation to cardiovascular dysfunction and severity of disease. Gut 2003; 52:1511-1517.
20. Runyon BA. Management of adult patients with ascites caused by cirrhosis. Hepatology 1998; 27:264-272.
21. Moreau R, Asselah T, Condat B, de Kerguenec C, Pessione F, Bernard B, et al. Comparison of the effect of terlipressin and albumin on arterial blood volume in patients with cirrhosis and tense ascites treated by paracentesis: a randomised pilot study. Gut 2002; 50:90-94.
22. La Villa G, Barletta G, Pantaleo P, Del Bene R, Vizzutti F, Vecchiarino S, et al. Hemodynamic, renal, and endocrine effects of acute inhibition of nitric oxide synthase in compensated cirrhosis. Hepatology 2001; 34:19-27.
23. Thiesson HC, Skott O, Jespersen B, Schaffalitzky de Muckadell OB. Nitric oxide synthase inhibition does not improve renal function in cirrhotic patients with ascites. Am J Gastroenterol 2003; 98:180-186.
24. Cabrera J, Arroyo V, Ballesta AM, Rimola A, Gual J, Elena M, Rodes J. Aminoglycoside nephrotoxicity in cirrhosis. Value of urinary beta 2-microglobulin to discriminate functional renal failure from acute tubular damage. Gastroenterology 1982; 82:97-105.
25. McCormick PA, Greenslade L, Kibbler CC, Chin JK, Burroughs AK, McIntyre N. A prospective randomized trial of ceftazidime versus netilmicin plus mezlocillin in the empirical therapy of presumed sepsis in cirrhotic patients. Hepatology 1997; 25:833-836.
26. Moore KP, Wong F, Gines P, Bernardi M, Ochs A, Salerno F, et al. The management of ascites in cirrhosis: report on the consensus conference of the International Ascites Club. Hepatology 2003; 38:258-266.
27. Felisart J, Rimola A, Arroyo V, Perez-Ayuso RM, Quintero E, Gines P, Rodes J. Cefotaxime is more effective than is ampicillin-tobramycin in cirrhotics with severe infections. Hepatology 1985; 5:457-462.
28. Grange JD, Amiot X, Grange V, Gutmann L, Biour M, Bodin F, Poupon R. Amoxicillin-clavulanic acid therapy of spontaneous bacterial peritonitis: a prospective study of twenty-seven cases in cirrhotic patients. Hepatology 1990; 11:360-364.
29. Terg R, Cobas S, Fassio E, Landeira G, Rios B, Vasen W, et al. Oral ciprofloxacin after a short course of intravenous ciprofloxacin in the treatment of spontaneous bacterial peritonitis: results of a multicenter, randomized study. J Hepatol 2000; 33:564-569.
30. Ricart E, Soriano G, Novella MT, Ortiz J, Sabat M, Kolle L, et al. Amoxicillin-clavulanic acid versus cefotaxime in the therapy of bacterial infections in cirrhotic patients. J Hepatol 2000; 32:596-602.
31. Sort P, Navasa M, Arroyo V, Aldeguer X, Planas R, Ruiz-del-Arbol L, et al. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med 1999; 341:403-409.